Several single‐node PAM inhibitors are FDA‐approved for advanced breast cancer in combination with hormonal therapy, including everolimus (mTORC1 inhibitor), alpelisib (PI3Kα inhibitor), and capivasertib (AKT inhibitor). The gene discussed is AKT1; the disease is breast cancer.